Navigation Links
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/26/2009

rtunistic infections, in patients with moderate or severe heart failure (NYHA Class III/IV), as well as in patients who are hypersensitive to SIMPONI or any of its excipients. Serious infections, including sepsis, pneumonia, tuberculosis, invasive fungal and other opportunistic infections have been observed with the use of TNF antagonists including SIMPONI. Some of these infections have been fatal. SIMPONI should not be given to patients with a clinically important, active infection. Caution should be exercised when considering the use of SIMPONI in patients with a chronic infection or a history of recurrent infection. Patients should be monitored for signs and symptoms of infection before, during and after treatment with SIMPONI. If a patient develops a serious infection or sepsis, SIMPONI therapy should be discontinued and appropriate antimicrobial therapy should be initiated. Patients should be advised of and avoid exposure to potential risk factors for infection as appropriate. For patients who have resided in or traveled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of SIMPONI treatment should be carefully considered before initiation of SIMPONI therapy. Patients must be evaluated for the risk of tuberculosis (TB), including latent tuberculosis, prior to initiation of SIMPONI. If active TB is diagnosed, SIMPONI must not be initiated. If latent TB is suspected then the benefit/risk balance should be considered for the following: treatment of latent tuberculosis infection should be initiated prior to therapy with SIMPONI. Antituberculosis therapy prior to initiating SIMPONI should also be considered in patients who have several or highly significant risk factors for tuberculosis infection and have a negative test for latent tuberculosis. Patients receiving SIMPONI should be monitored closely for signs and symptoms of active tuberculosis during and af
'/>"/>
SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Berger & Montague, P.C., a full-spectrum class ... one of the largest and most successful whistleblower ... Faruqi, LLP in settling three separate but related ... Cephalon, Inc., and Biogen, Inc., for a total ... agreements, AstraZeneca will pay the largest sum, $46.5 ...
(Date:7/7/2015)... July 7, 2015 A power morcellator lawsuit ... been settled for an undisclosed amount, Bernstein Liebhard LLP ... in March 2014 in the U.S. District Court, Eastern ... of a widower whose wife had died in February ... hysterectomy that involved the use of a power morcellator. ...
(Date:7/7/2015)... Juli 2015 Sequent Medical, ein ... Entwicklung innovativer Geräte für die Behandlung neurovaskulärer ... von R. Michael Kleine in den ... verfügt über eine mehr als 25-jährige Erfahrung ... hat verschiedene globale biomedizinische Unternehmen erfolgreich geleitet ...
Breaking Medicine Technology:AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 2AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 3Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3
... a wholly-owned subsidiary of Integrated BioPharma,Inc. (NASDAQ: ... of vaccines against HPV, anthrax and plague ... The,studies were conducted by the Fraunhofer USA ... Organization led by Dr.,Vidadi Yusibov, through which ...
... Profile and Excellent,Pharmacokinetic Properties -, RESEARCH TRIANGLE PARK, ... a clinical stage company developing and,commercializing innovative treatments ... top-line results from a Phase I,clinical trial of ... and anxiety. In this study, Tyrima was safe ...
Cached Medicine Technology:Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time ... so Amica Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator ... Leisure activities/sports, , Start slowly. Going from no activity to ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, ... at the Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted ... cause, helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is ...
(Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today ... destination for HSA holders. HSAstore.com makes it simple to use, spend and manage HSA ... better understand their accounts. , According to a report by Devenir , ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri ... whitening treatments. A professional teeth whitening is one of the fastest, easiest ways to ... as they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, ...
(Date:7/7/2015)... TX (PRWEB) , ... July 07, 2015 , ... ... inroads into potentially explosive environments with the introduction of the Nightstick XPP-5422GM ... to feature dual magnets, one at its base and one on its clip. ...
Breaking Medicine News(10 mins):Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3
... Oct. 15 DSS Research asked a number,of questions ... in their June Senior Trax(TM) survey. The study was ... 13.3% said they,had heard or read some kind of ... This figure ranged from a high of 28.8% for ...
... today announced it will host a webcast and conference call at 10 am,ET ... 2007, which ended September 30. Financial results are,scheduled for release after the market ... Chairman and CEO, WHEN: Friday, November 2, 2007 ... HOW: Presentation: ...
... Mental Health Conference in Melville, New ... 15 In recognition of National Mental,Illness Awareness Week, ... by Clubhouse of Suffolk, Inc., will be held on,Friday, ... NY from 8:00,AM to 4:00 PM. More than 1,000 ...
... Disability Management Employer,Coalition (DMEC), the leading advocate ... and disability related employer programs, today,announced that ... growing association.,Michael Klachefsky, Mercer principal and senior ... Board effective October 1,2007. "The addition ...
... Aspirin, ibuprofen and similar medicines pose big stomach risks, ... -- Large numbers of patients don,t tell their doctors ... and ibuprofen, a potentially dangerous omission, a new study ... patients underreporting their medicine intake, it is no wonder ...
... teenagers aged 12-18 claim to have been victims of some ... by the University of Haifa and Ben Gurion University. The ... boys and 76% of the girls reported said that they ... Rachel Lev-Wiesel from the University of Haifa,s School of Social ...
Cached Medicine News:Health News:HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation 2Health News:Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 2Health News:Disability Management Employer Coalition Names Mercer as Newest Platinum Sponsor 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Almost 90 percent of children reported experiencing sexual violence 2
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
250L...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: